Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Short Interest Update

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 21,160 shares, a decrease of 35.1% from the June 15th total of 32,585 shares. Based on an average trading volume of 2 shares, the short-interest ratio is currently 10,580.0 days.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Towa Pharmaceutical to an “overweight” rating in a research note on Friday, June 12th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, Towa Pharmaceutical has an average rating of “Buy”.

Towa Pharmaceutical Price Performance

TWAPF stock opened at $26.00 on Friday. The firm has a 50 day simple moving average of $25.46 and a two-hundred day simple moving average of $25.37. Towa Pharmaceutical has a one year low of $25.71 and a one year high of $26.00.

Towa Pharmaceutical Company Profile

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.